NDAORALTABLET, EXTENDED RELEASE
Approved
Jul 2016
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
2/8 — Basic
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VIEKIRA XR is a fixed-dose combination oral tablet containing dasabuvir, ombitasvir, paritaprevir, and ritonavir approved by the FDA in July 2016. This is a direct-acting antiviral (DAA) combination therapy for hepatitis C virus (HCV) infection. The extended-release formulation enables simpler dosing and improved patient compliance in chronic HCV management.
Peak8.7 years to LOE
Product is in peak commercial phase with mature market positioning; commercial teams are focused on market maintenance and patient retention rather than growth acceleration.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on VIEKIRA XR offers stable, mature commercial experience in specialty pharmaceuticals with established prescriber networks and patient populations. Career growth depends on leveraging peak-stage commercial expertise toward product lifecycle extension, portfolio expansion, or transition into emerging viral infection therapies.
Brand ManagerField Sales Representative
Worked on VIEKIRA XR at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.